Free energy calculations on the binding of colchicine and its derivatives with the alpha/beta-tubulin isoforms

Journal of Chemical Information and Modeling
Jonathan Y ManeJack A Tuszynski

Abstract

Tubulin is the target for numerous small molecule ligands which alter microtubule dynamics leading to cell cycle arrest and apoptosis. Many of these ligands are currently used clinically for the treatment of several types of cancer, and they bind to one of three distinct binding sites within beta-tubulin (paclitaxel, vinca, and colchicine), all of which have been identified crystallographically. Unfortunately, serious side effects always accompany chemotherapy since these drugs bind to tubulin indiscriminately, leading to the death of both cancerous and healthy cells. However, the existence and distribution of divergent tubulin isoforms provide a platform upon which we may build novel chemotherapeutic drugs that can differentiate between different cell types and therefore reduce undesirable side effects. We report results of computational analysis that aims at predicting differences between the binding energies of a family of colchicine derivatives against 10 human alpha/beta-tubulin isoforms. Free energy perturbation method has been used in our calculations and the results provide a proof of principle by indicating significant differences both among the derivatives and between tubulin isoforms.

References

Mar 5, 1992·Nature·R LüthyD Eisenberg
May 1, 1990·Archives of Otolaryngology--head & Neck Surgery·C A ScottP A Levine
Jan 1, 1991·Pharmacology & Therapeutics·R F Luduena, M C Roach
Nov 15, 1984·Nature·T Mitchison, M Kirschner
Nov 22, 1994·Proceedings of the National Academy of Sciences of the United States of America·D PandaL Wilson
Dec 5, 1993·Journal of Molecular Biology·A Sali, T L Blundell
May 23, 1996·Nature·R W HooftE E Abola
May 8, 1998·Biochemical and Biophysical Research Communications·A Banerjee, L T Kasmala
Mar 18, 2000·Journal of Computer-aided Molecular Design·G Schaftenaar, J H Noordik
Nov 4, 2000·Journal of Molecular Biology·A R ChaudhuriR F Ludueña
Jul 27, 2001·The Journal of Surgical Research·B LiuJ M Howard
Nov 9, 2001·Journal of Molecular Biology·J LöweE Nogales
Dec 13, 2002·Proceedings of the National Academy of Sciences of the United States of America·Robert L StrausbergUNKNOWN Mammalian Gene Collection Program Team
Jun 11, 2003·Investigational New Drugs·Israr A Khan, Richard F Ludueña
Aug 9, 2003·Cell Motility and the Cytoskeleton·Malathi HariFernando Cabral
Sep 23, 2003·Protein Science : a Publication of the Protein Society·David SeptJ Andrew McCammon
Dec 19, 2003·Nucleic Acids Research·Rolf ApweilerLai-Su L Yeh
Apr 2, 2004·Nature Reviews. Cancer·Mary Ann Jordan, Leslie Wilson
May 27, 2005·Nature·Benoît GigantMarcel Knossow
Feb 27, 2007·Journal of Molecular Biology·Jeffery B Klauda, Bernard R Brooks
Jun 9, 2007·The Journal of Physical Chemistry. a·H Lee WoodcockBernard R Brooks
Feb 28, 2006·Nanotechnology·J Torin HuzilJack Tuszynski
Jan 1, 2007·Journal of Chemical Theory and Computation·Bojan Zagrovic, Wilfred F van Gunsteren

❮ Previous
Next ❯

Citations

Jun 27, 2012·Pharmaceutical Research·Melissa M GajewskiJack A Tuszynski
Jun 12, 2014·Journal of Computer-aided Molecular Design·Seneha Santoshi, Pradeep K Naik
Aug 3, 2017·International Journal of Molecular Sciences·Ivana SpasevskaJack A Tuszynski
Oct 13, 2011·ChemMedChem·Alberto MassarottiAndrea Brancale
Jan 25, 2012·Chemical Biology & Drug Design·Douglas E FriesenJack A Tuszynski
Jan 2, 2019·International Journal of Molecular Sciences·Fangfang WangXiaojun Hu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis